Department of Interventional Radiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Department of Interventional Radiology, the Fourth Medical Center of PLA General Hospital, Beijing, China.
Aesthetic Plast Surg. 2021 Aug;45(4):1573-1578. doi: 10.1007/s00266-021-02224-4. Epub 2021 Mar 26.
To evaluate the efficacy and safety of recanalizing hyaluronic acid-occluded retinal central artery by intra-arterially infusing hyaluronidase.
Between December 2015 and December 2016, 30 patients with monocular blindness due to the injection of hyaluronic acid in facial tissue underwent ophthalmic artery recanalization. The outcome of the intra-arterial treatment was retrospectively reviewed. The fundus was examined 24 hours after the treatment to observe revisualization of the retinal arteries. The success rate of intra-arterial recanalization of the ophthalmic artery, procedure-related complications, visual acuity recovery, eyeball and eyelid movement restoration was followed up for up to 3 months.
The success rate of ophthalmic arterial catheterization was 100%. No interventional procedure-related adverse events were found. Twenty-six patients presented ptosis and 23 patients presented ocular motility disorders. The ptosis disappeared and 18 patients had normal eye movement after the intra-arterial therapy. Five of the 30 patients had visual improvement and four patients with complete vision loss gained some light perception. After the intra-arterial thrombolysis, digital subtraction angiographic imaging revealed enlarged and numerous branches of the ophthalmic artery and a clearer ring around the eye.
Intra-arterial infusion of hyaluronidase and mechanical recanalization is an effective and safe approach for recovering the visual acuity in the patients with monocular blindness caused by the migration of hyaluronic acid injected in the facial tissues.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
评估经动脉内注射透明质酸酶疏通透明质酸阻塞的视网膜中央动脉的疗效和安全性。
2015 年 12 月至 2016 年 12 月,30 例因面部组织注射透明质酸导致单眼失明的患者接受了眼动脉再通治疗。回顾性分析了经动脉治疗的结果。治疗后 24 小时检查眼底,观察视网膜动脉再通情况。随访眼动脉再通的成功率、与介入治疗相关的并发症、视力恢复、眼球和眼睑运动恢复情况,最长随访 3 个月。
眼动脉导管插入术成功率为 100%。未发现与介入治疗相关的不良事件。26 例患者出现上睑下垂,23 例患者出现眼球运动障碍。经动脉治疗后,上睑下垂消失,18 例患者眼球运动正常。30 例患者中有 5 例视力改善,4 例完全失明患者获得了一定程度的光感。经动脉溶栓后,数字减影血管造影显示眼动脉扩张、分支增多,眼部周围环影清晰。
经动脉内注射透明质酸酶联合机械再通是一种有效、安全的方法,可恢复因面部组织注射透明质酸迁移导致单眼失明患者的视力。
证据水平 IV:本杂志要求作者为每篇文章分配一个证据水平。有关这些循证医学评级的完整描述,请参考目录或在线作者指南 www.springer.com/00266 。